At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
ARS-1drug
Likely dose
ARS-1 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Dose, Randomized, Placebo-Controlled, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares
In Brief
A Phase 2 clinical trial evaluating ARS-1 for Urticaria. Completed, enrolled 21 participants across 2 sites.
Detailed Summary
Determine the effect of ARS-1 on a patient reported pruritus/hive score
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrticaria
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartJul 2022
First PostedAug 2022
Primary CompletionFeb 2024
TodayJul 2026
First PostedAug 11, 2022
Enrollment StartJul 28, 2022
Primary CompletionFeb 29, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.9 years ago
Interventions
ARS-1drug
A single treatment of ARS-1 1mg, 2 mg or placebo